CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The Science Underlying COVID-19: Implications for the Cardiovascular System Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials Association Between Depressive Symptoms and Incident Cardiovascular Diseases Impact of Percutaneous Revascularization on Exercise Hemodynamics in Patients With Stable Coronary Disease Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial When, where, and how to target vascular inflammation in the post-CANTOS era? Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: A national multicenter study Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY

Original Research2018 Nov 15;271:181-185.

JOURNAL:Int J Cardiol. Article Link

Heart rate, pulse pressure and mortality in patients with myocardial infarction complicated by heart failure

Dobre D, Kjekshus J, Rossignol P et al. Keywords: Heart failure; Heart rate; Myocardial infarction; Pulse pressure

ABSTRACT


OBJECTIVE - To assess the relationship between heart rate (HR), pulse pressure (PP), and their association with mortality in a population of high-risk patients following acute myocardial infarction (MI).


METHODS - We performed an analysis in 22,398 patients included in "The High-Risk Myocardial Infarction Database Initiative", a database of clinical trials evaluating pharmacologic interventions in patients with MI complicated by signs of heart failure (HF) or left ventricular dysfunction. We found an interaction between HR and PP. Based on median HR and median PP, patients were divided in four categories: (1) HR < 75 bpm and PP ≥ 50 mm Hg (reference), (2) HR < 75 bpm and PP < 50 mm Hg, (3) HR ≥ 75 bpm and PP ≥ 50 mm Hg, and (4) HR ≥ 75 bpm and PP < 50 mm Hg. The association between these categories and outcomes was studied using a Cox proportional hazard model.


RESULTS - After a median follow-up of 24 (18-33) months, 3561 (16%) patients died of all-causes and 3048 (14%) patients of cardiovascular (CV) causes. In multivariate analysis, patients from the fourth category had the highest risk of all-cause mortality (hazard ratio of 1.69; 95% CI: 1.53-1.86) and CV mortality (hazard ratio of 1.78; 95% CI: 1.60-1.97).


CONCLUSIONS - There is an interaction between HR and PP in patients with HF following MI, with the highest risk being conferred by a clinical status with both an elevated HR and a lower PP. These findings identify a high-risk population likely to require an aggressive diagnostic and management strategy.


Copyright © 2018. Published by Elsevier B.V.